 |
| AGENDA | |
| | |
| 12:30 – 1:30 | Registration |
| 1:30 – 1:40
| Welcome
Bob Buderi, Editor in Chief, Xconomy |
| 1:40 – 1:50 | Opening Remarks
Douglas Williams, EVP, Research and Development, Biogen Idec |
| 1:50 – 2:15
| Profile 1: RNAi Therapeutics, Alnylam, and The Carrot Seed
John Maraganore, CEO, Alnylam Pharmaceuticals
|
| 2:15 – 2:45 | Panel: New Models for Collaboration
Richard Brudnick, VP, Business Development, Biogen Idec
Robert Urban, Head, J&J Innovation Center, Boston
Jason Rhodes, President and CFO, Epizyme
Rob Armstrong, former VP, Global External Research and Development, Eli Lilly (moderator)
|
| 2:45 – 3:15
| Chat: Thoughts on the Past, Present, and Future of Biotech
Michael Bonney, CEO, Cubist Pharmaceuticals
Bob Buderi, Editor in Chief, Xconomy (moderator)
|
| 3:15 – 3:45 | Networking Break |
| 3:45 – 4:10 | Profile 2: Gene Surgery With CRISPR/Cas9: The Editas Medicine Story
Kevin Bitterman, Interim CEO, Editas Medicine; Partner, Polaris Partners
Feng Zhang, Professor of Biomedical Engineering, MIT |
| 4:10 – 4:35 | Profile 3: Gene Regulation and Contrarian Drug Development: The Syros Pharmaceuticals Story
Nancy Simonian, CEO, Syros Pharmaceuticals |
| 4:35 – 5:05 | Panel: New Alternatives for Financing
Roger Stein, Chief Analytics Officer, State Street Global Exchange
Katrine Bosley, Entrepreneur-in-residence, The Broad Institute (moderator) | |
| 5:05 – 5:30 | Profile 4: A Bottoms-Up View of the Microbiome: The Seres Health Story
David Berry, CEO, Seres Health; Partner, Flagship Ventures | |
| 5:30 – 6:30 | Networking Reception |
| | |
| REGISTER NOW: xconomyforum68.eventbrite.com |
|
